Mibefradil (Di HCl)
Mibefradil (Di HCl) is a calcium-channel blocking agent, that primarily acts on fast T-type calcium channels. It was introduced for the management of hypertension and angina pectoris. The drug has been withdrawn from market due to increasing reports of serious interactions with wide range of drugs.
Primary Characteristics
It is of Synthetic origin.
It is also classified under Calcium Channel Blocker .
Molecular Weight: 568.56 · Solubility in Alcohol: > 1 in 5 · Non-proprietary name: Mibefradil (Di HCl).
Pharmacokinetics
Absorption: Mibefradil (Di HCl) has an oral bioavailability is 50% (±50%), pre-systemic (first-pass) metabolism accounts for 15% (±15%).
Distribution: Mibefradil (Di HCl) has a volume of distribution is 130 - 200 litre. plasma protein binding is 99 %.
Elimination: plasma half-life is 15 hr, renal excretion is 3 % unchanged.
Advertisement
Indications
Mibefradil (Di HCl) is primarily indicated in conditions like Angina, Essential hypertension.
Mibefradil (Di HCl) is also indicated for secondary conditions like Congestive heart failure.
Contraindications
Mibefradil (Di HCl) is contraindicated in conditions like Myocardial infarction, Sick sinus syndrome, Second or third degree A-V block, Hepatic impairment, Hypersensitivity, Pregnancy, Lactation, Moderate to severe heart failure.
Dosage
Mibefradil (Di HCl)'s dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 75 mg | 75 mg | Every 24h | ||
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Mibefradil (Di HCl) produces potentially life-threatening effects which include Symptomatic slow junctional rhythm. Careful monitoring is needed with proper medical management.
The signs and symptoms that are produced after acute overdosage of Mibefradil (Di HCl) are Bradycardia, Peripheral vasodilation, Hypotension, High degree AV block.
Mibefradil (Di HCl) is known to cause more or less tolerable side effects which are usually transient. These include Angioedema, Dizziness, Fatigue, Headache, Leg edema, Thrombocytopenia.
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.12.3.2 — Calcium antagonists